Guggenheim Maintains Buy on Neurocrine Biosciences, Raises Price Target to $180
Portfolio Pulse from Benzinga Newsdesk
Guggenheim analyst Yatin Suneja maintains a Buy rating on Neurocrine Biosciences (NASDAQ:NBIX) and raises the price target from $170 to $180.
August 02, 2024 | 7:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Guggenheim analyst Yatin Suneja maintains a Buy rating on Neurocrine Biosciences and raises the price target from $170 to $180.
The Buy rating and increased price target from a reputable analyst at Guggenheim is likely to positively influence investor sentiment and drive short-term price appreciation for NBIX.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100